Role of VEGF and CD44v6 in differentiating benign from malignant ascites

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 11

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

222

HTML

1938

Figures (1-3)

183

Tables (1-1)

181

Sum=2524

Nov 15, 2003 (publication date) through Nov 19, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Research

World J Gastroenterol. Nov 15, 2003; 9(11): 2596-2600
Published online Nov 15, 2003. doi: 10.3748/wjg.v9.i11.2596

Table 1 Patient characteristics

Diagnosis	No. of Patients	Mean age (range)	Female/male
Ascite	67	47 (19-86)	26/41
Cirrhotic ascites	36	48 (30-86)	10/26
Tuberculous ascites	8	28 (19-33)	4/4
Carcinoma ascites	23	66 (35-76)	12/11
Ovarian cancer	8	60 (35-70)	8/0
Gastric cancer	6	68 (38-74)	1/5
Colon cancer	5	64 (48-71)	2/3
Hepatocellular cancer	2	-	0/2
Pancreatic cancer	1	-	0/1
Primary peritoneal carcinoma	1	-	1/0

Citation: Dong WG, Sun XM, Yu BP, Luo HS, Yu JP. Role of VEGF and CD44v6 in differentiating benign from malignant ascites. World J Gastroenterol 2003; 9(11): 2596-2600
URL: https://www.wjgnet.com/1007-9327/full/v9/i11/2596.htm
DOI: https://dx.doi.org/10.3748/wjg.v9.i11.2596